Further, although no differences were noticed between groups in plasmatic neurofilamentlight chain (Nfl) concentration (Supplementary Figure S4), nor in patients’ burden in genes at risk (MSGB), using the most recent associated SNPs set from the International Multiple Sclerosis Genetics Consortium (41) (Figure 3C, left), we found that 75% of MS patients with CD206hi CD209hi Mo carry either HLA-DRB1*15:01 and/or HLA-DQB1*06:02 compared to 45% in MS patients with CD206hi CD209hi Mo (p < 0.001) (Figure 3C, right). Here, HLA-DRB1 is linked to myeloid sarcoma.